N-乙基-4-硼苯磺酰胺 | 871329-65-6

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-4-硼苯磺酰胺
• 中文别名: 4-(乙基磺酰胺基)苯硼酸；4-(N-乙基磺酰胺)苯硼酸
• 英文名称: [4-(ethylsulfamoyl)phenyl]boronic acid
• 英文别名: (4-(N-Ethylsulfamoyl)phenyl)boronic acid
• CAS: 871329-65-6
• 化学式: C₈H₁₂BNO₄S
• mdl: MFCD07363751
• 分子量: 229.065
• InChiKey: YVKVLCDUDPTJEW-UHFFFAOYSA-N

物化性质

• 熔点：
  132-136
• 沸点：
  424.9±55.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.86
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  95
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Ethyl 4-boronobenzenesulfonamide
Product Name:
Synonyms: 4-N-Ethylsulfamoylphenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Ethyl 4-boronobenzenesulfonamide
Ingredient name:
CAS number: 871329-65-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H12BNO4S
Molecular weight: 229.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  N-乙基-4-溴苯磺酰胺	4-bromo-N-ethylbenzenesulfonamide	1984-25-4	C8H10BrNO2S	264.143

反应信息

• 作为反应物：
  描述：

  N-乙基-4-硼苯磺酰胺 、 1-(3-bromo-5-chlorophenyl)cyclobutanecarboximidamide hydrochloride 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium dihydrogenphosphate 、 1,3,5,7-四甲基-6-苯基-2,4,8-三氧杂-6-磷酰金刚烷 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.0h， 以25%的产率得到1-(5-chloro-4′-(N-ethylsulfamoyl)-[1,1′-biphenyl]-3-yl)-cyclobutane-1-carboximidamide
  参考文献：
  名称：

  Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer

  摘要：

  Apolipoprotein E is a 299-residue lipid carrier protein produced in both the liver and the brain. The protein has three major isoforms denoted apoE2, apoE3, and apoE4 which differ at positions 112 and 158 and which occur at different frequencies in the human population. Genome-wide association studies indicate that the possession of two apoE4 alleles is a strong genetic risk factor for late-onset Alzheimer's disease (LOAD). In an attempt to identify a small molecule stabilizer of apoE4 function that may have utility as a therapy for Alzheimer's disease, we carried out an NMR-based fragment screen on the N-terminal domain of apoE4 and identified a benzyl amidine based fragment binder. In addition to NMR, binding was characterized using various other biophysical techniques, and a crystal structure of the bound core was obtained. Core elaboration ultimately yielded a compound that showed activity in an IL-6 and IL-8 cytokine release assay.

  DOI：

  10.1021/acs.jmedchem.9b00178
• 作为产物：
  描述：

  4-溴苯磺酰氯 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-乙基-4-硼苯磺酰胺
  参考文献：
  名称：

  靶向丝裂原活化蛋白激酶激酶 4 (MKK4) 的 1H-吡唑并[3,4-b]吡啶的设计和合成——肝再生的一个有希望的靶点

  摘要：

  目前，治疗肝功能衰竭的治疗选择非常有限。由于最近通过体内RNAi 实验发现丝裂原活化蛋白激酶激酶 4 (MKK4)是肝细胞再生的主要调节因子，因此我们致力于开发一种针对该蛋白激酶的小分子。从已获批的 BRAF V600E抑制剂 vemurafenib ( 8 )开始，该抑制剂在初始筛选中显示出对 MKK4 的高脱靶亲和力，我们采用了支架跳跃方法，将核心杂环从 1 H -吡咯 [2,3- b ]吡啶到 1 H-吡唑并[2,3- b ]吡啶（10）。对 MKK4 的亲和力可以得到保留，而对脱靶蛋白激酶的选择性略有提高。进一步的修改导致58和59在低纳摩尔范围内显示出对 MKK4 的高亲和力，以及来自必需抗靶点（MKK7、JNK1）和脱靶点（BRAF、MAP4K5、ZAK）的强制性多参数优化的优异选择性。 MKK4 通路。在此我们报告了此类中的第一个选择性 MKK4 抑制剂。

  DOI：

  10.1016/j.ejmech.2021.113371

文献信息

• [EN] PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH<br/>[FR] INHIBITEURS DE PROTÉINE KINASE MKK4 POUR FAVORISER LA RÉGÉNÉRATION HÉPATIQUE OU POUR RÉDUIRE OU PRÉVENIR LA MORT DES HÉPATOCYTES
  申请人：HEPAREGENIX GMBH

  公开号：WO2019149738A1

  公开（公告）日：2019-08-08

  The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

  这项发明涉及抑制有丝分裂原活化蛋白激酶激酶4（MKK4）的吡唑啉-吡啶化合物，特别是选择性地抑制MKK4而不影响蛋白激酶JNK1和MKK7。这些化合物可用于促进肝再生或减少或预防肝细胞死亡。它们还可用于治疗骨关节炎或类风湿性关节炎，或中枢神经系统相关疾病。
• Design and Evaluation of Novel Biphenyl Sulfonamide Derivatives with Potent Histamine H₃ Receptor Inverse Agonist Activity
  作者：Jonathan A. Covel、Vincent J. Santora、Jeffrey M. Smith、Rena Hayashi、Charlemagne Gallardo、Michael I. Weinhouse、Jason B. Ibarra、Jeffrey A. Schultz、Douglas M. Park、Scott A. Estrada、Brian J. Hofilena、Michelle D. Pulley、Brian M. Smith、Albert Ren、Marissa Suarez、John Frazer、Jeffrey Edwards、Erin K. Hauser、Jodie Lorea、Graeme Semple、Andrew J. Grottick

  DOI：10.1021/jm900857n

  日期：2009.9.24

  Phenethyl-R-2-methylpyrrolidine containing biphenylsulfonamide compounds were shown to be potent and selective antagonists of the H3 receptor. Several of these compounds demonstrated in vivo activity in a rat model of (R)-α-methyl histamine (RAMH) induced dipsogenia, and one compound (4e) provided an increase in wakefulness in rats as measured by polysomnographic methods. However, more detailed analysis of the PK/PD

  组胺-H 3受体的拮抗作用是探索增加清醒性以治疗诸如过度日间嗜睡（EDS）以及其他睡眠或认知障碍之类的疾病的一种策略。含有苯乙基-R -2-甲基吡咯烷的联苯磺酰胺化合物被证明是H 3受体的有效和选择性拮抗剂。这些化合物中的几种在（R）-α-甲基组胺（RAMH）诱导的成瘾症的大鼠模型中具有体内活性，一种化合物（4e）通过多导睡眠监测法测量了大鼠的清醒度。但是，对PK / PD关系的更详细分析表明存在共同的活性代谢物，这可能会使该系列化合物无法进一步开发。
• Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration
  作者：Bent Pfaffenrot、Philip Klövekorn、Michael Juchum、Roland Selig、Wolfgang Albrecht、Lars Zender、Stefan A. Laufer

  DOI：10.1016/j.ejmech.2021.113371

  日期：2021.6

  vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity

  目前，治疗肝功能衰竭的治疗选择非常有限。由于最近通过体内RNAi 实验发现丝裂原活化蛋白激酶激酶 4 (MKK4)是肝细胞再生的主要调节因子，因此我们致力于开发一种针对该蛋白激酶的小分子。从已获批的 BRAF V600E抑制剂 vemurafenib ( 8 )开始，该抑制剂在初始筛选中显示出对 MKK4 的高脱靶亲和力，我们采用了支架跳跃方法，将核心杂环从 1 H -吡咯 [2,3- b ]吡啶到 1 H-吡唑并[2,3- b ]吡啶（10）。对 MKK4 的亲和力可以得到保留，而对脱靶蛋白激酶的选择性略有提高。进一步的修改导致58和59在低纳摩尔范围内显示出对 MKK4 的高亲和力，以及来自必需抗靶点（MKK7、JNK1）和脱靶点（BRAF、MAP4K5、ZAK）的强制性多参数优化的优异选择性。 MKK4 通路。在此我们报告了此类中的第一个选择性 MKK4 抑制剂。
• Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer
  作者：Andrew M. Petros、Alla Korepanova、Clarissa G. Jakob、Wei Qiu、Sanjay C. Panchal、Jie Wang、Justin D. Dietrich、Jason T. Brewer、Frauke Pohlki、Andreas Kling、Kyle Wilcox、Viktor Lakics、Lamiaa Bahnassawy、Peter Reinhardt、Sarathy Karunan Partha、Pierre M. Bodelle、Marc Lake、Erik I. Charych、Vincent S. Stoll、Chaohong Sun、Eric G. Mohler

  DOI：10.1021/acs.jmedchem.9b00178

  日期：2019.4.25

  Apolipoprotein E is a 299-residue lipid carrier protein produced in both the liver and the brain. The protein has three major isoforms denoted apoE2, apoE3, and apoE4 which differ at positions 112 and 158 and which occur at different frequencies in the human population. Genome-wide association studies indicate that the possession of two apoE4 alleles is a strong genetic risk factor for late-onset Alzheimer's disease (LOAD). In an attempt to identify a small molecule stabilizer of apoE4 function that may have utility as a therapy for Alzheimer's disease, we carried out an NMR-based fragment screen on the N-terminal domain of apoE4 and identified a benzyl amidine based fragment binder. In addition to NMR, binding was characterized using various other biophysical techniques, and a crystal structure of the bound core was obtained. Core elaboration ultimately yielded a compound that showed activity in an IL-6 and IL-8 cytokine release assay.